Clinical trial registry record

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 12, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01003691
Last registry update
May 12, 2022
Status
Completed
Phase
Phase 1
Sponsor
Pfizer
Enrollment
24
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · SEQUENTIAL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
24
Population
ALL · 60 Years to 85 Years
Duration
2010-08-05 to 2013-04-19
Intervention
RN6G; Placebo
Comparator
Not reported
Outcomes measured
Number of Participants With Toxicity or Intolerable Dose Criteria — Baseline up to Day 304/End of Treatment (ET); Number of Participants With Treatment Emergent Adverse Events (TEAEs) Categorized by Severity — Baseline up to Day 304/…; Number of Participants With Treatment Emergent Adverse Events (TEAEs): All Causalities and TEAEs Categorized by Causal…; Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) Categorized by Severity — Baseline up to D…; Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) Categorized by Causal Relationship to Stud…; Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Categorized by Severity — Baseline up to…; Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Categorized by Causal Relationship to St…; Number of Participants With Positive Anti-Drug-Antibodies (ADA) and Neutralizing Antibodies (Nab) — Baseline up to Day…; Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day…; Maximum Observed Plasma Concentration (Cmax) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,140; Pos…; Minimum Observed Plasma Trough Concentration (Cmin) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,1…; Plasma Concentration (Css) at Steady State of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,140; Post-…; Time to Reach Maximum Observed Plasma Concentration (Tmax) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 8…; Volume of Distribution at Steady State (Vss) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,140; Pos…; Mean Residence Time (MRT) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,140; Post-dose: 1, 2, 4, 24…; Systemic Clearance (CL) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,140; Post-dose: 1, 2, 4, 24,…; Plasma Decay Half-Life (t1/2) of RN6G (PF-04382923) — Pre-dose: 0 hour on Day 1, 28, 56, 84,112,140; Post-dose: 1, 2, 4…; Change From Baseline in Plasma Total Amyloid (A) Beta (1-X) Concentration at Day 1, 2, 7, 14, 19, 28, 45, 56, 75, 84, 1…; Percent Change From Baseline in Plasma Total Amyloid (A) Beta (1-X) Concentration at Day 1, 2, 7, 14, 19, 28, 45, 56, 7…; Change From Baseline in Plasma Amyloid (A) Beta (1-40) Concentration at Day 1, 2, 7, 14, 19, 28, 45, 56, 75, 84, 103, 1…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON